Inferra AI / Company / BCPC
Balchem Corp
BCPC · Materials
Last earnings Oct 23, 2026
Key results
Revenuequarter
$290.7 million
For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash flow (a) of $57.9 million.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Net incomequarter
$46.7 million
For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash flow (a) of $57.9 million.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
GAAP net incomequarter
$46.7 million
GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year quarter.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
EPSquarter
$1.46
GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share (a) were $1.57 compared to $1.35 in the prior year quarter.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Free cash flowquarter
$57.9 million
Cash flows from operations were $69.8 million, with free cash flow of $57.9 million.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Page 2 Balchem Corporation (NASDAQ BCPC) Financial Results for the Third Quarter of 2026 The Human Nutrition and Health segment generated record quarterly sales of $188.2 million, an increase of $14.1 million, or 8.1%, compared to the prior year quarter.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Record earnings from operationsquarter
$45.6 million
Record earnings from operations for this segment of $45.6 million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by higher operating expenses.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Adjusted earnings from operationsquarter
$48.9 million
Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations (a) for this segment were $48.9 million, compared to $44.1 million in the prior year quarter, an increase of 10.9%.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
The Animal Nutrition and Health segment generated quarterly sales of $63.0 million, an increase of $6.6 million, or 11.7%, compared to the prior year quarter.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
AI analysis
Q3 2026 · reported Oct 23, 2026
Based on: Earnings release + Q3 2026 deck + parent 8-K — transcript not held
The quarter in charts
Diluted EPS — GAAP
Per diluted share, as stated
EX-99 · Oct 23, 2026 EPS values as stated in the release.
Headline figures
| Metric | Q3 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $290.7 million | $284.0 million | — |
| Net income | $46.7 million | $44.6 million | — |
| GAAP net income | $46.7 million | $44.6 million | — |
| EPS | $1.46 | $1.39 | $1.24 |
| Free cash flow | $57.9 million | $36.2 million | — |
| Record earnings from operations | $45.6 million | $42.4 million | $40.8 million |
| Adjusted earnings from operations | $48.9 million | $45.9 million | $44.1 million |
Guidance · company-stated
No guidance located in the held release
Cash flow & capex
Capital allocation
Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.
Event summary
For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA (a) of $80.3 million, and free c ash flow (a) of $57.9 million
Based on: Earnings release + Q3 2026 deck + parent 8-K — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Significant cash payments during the quarter included net debt payments of $28.0 million, income taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and capital expenditures and intangible assets acquired of $12.5 million.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share repurchases or other financial items any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services any statements regarding future economic conditions or our performance any statements regarding pending investigations, claims or disputes any statements of expectation or belief and any statements of assumptions underlying any of the foregoing.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
The decrease in interest expense was primarily due to lower outstanding borrowings and lower interest rates.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Outstanding debt on our revolving loan was $124.0 million as of September 30, 2026 and our net debt (b) was $57.7 million, with an overall leverage ratio (c) on a net debt basis of 0.2 times.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
(b) Net debt is defined as the outstanding balance on our revolving loan less cash and cash equivalents.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Strategy & priorities
These innovations highlight the strength of our pipeline and our continued focus on developing differentiated, science-backed solutions that address important human health and wellness trends.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Harris added, With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Harris said, The Balchem team delivered another strong quarter in Q3 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
These forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate, forecast, outlook, intend, strategy, future, opportunity, plan, may, should, will, would, will be, will continue, will likely result, or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Risks & headwinds
They are subject to future events, risks and uncertainties - many of which are beyond the Company s control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
What changed vs prior quarter
Revenue — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
GAAP net income — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
EPS — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Balchem Corp — Earnings release (8-K exhibit)EX-99Oct 23, 2026
Earnings deck slides
1 deck with slide viewBalchem Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Balchem Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Balchem Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Balchem Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q3 2026
- 8-KBCPC
Oct 23, 2026
- Q2 2026
- 10-QBCPC
Jul 31, 2026
- 8-KBCPC
Jul 31, 2026
- 8-KBCPC
Jul 27, 2026
- Q1 2026
- 8-KBCPC
Jun 22, 2026
- 10-QBCPC
Apr 30, 2026
- 8-KBCPC
Apr 30, 2026
- Q4 2025
- 10-KBCPC
Feb 20, 2026
- 8-KBCPC
Feb 20, 2026
- 8-KBCPC
Feb 19, 2026
- Q3 2025
- 8-KBCPC
Dec 10, 2025
- 10-QBCPC
Oct 21, 2025
- 8-KBCPC
Oct 21, 2025
- Q2 2025
- 10-QBCPC
Jul 31, 2025
- 8-KBCPC
Jul 31, 2025
- Q1 2025
- 8-KBCPC
Jun 20, 2025
- 10-QBCPC
Apr 24, 2025
- 8-KBCPC
Apr 24, 2025
- Q4 2024
- 8-KBCPC
Mar 3, 2025
- 10-KBCPC
Feb 21, 2025
- 8-KBCPC
Feb 21, 2025
- 8-KBCPC
Feb 14, 2025
- Q3 2024
- 8-KBCPC
Dec 10, 2024
- 10-QBCPC
Oct 25, 2024
- 8-KBCPC
Oct 25, 2024
- 8-KBCPC
Oct 17, 2024
- Q2 2024
- 8-KBCPC
Sep 20, 2024
- 10-QBCPC
Jul 26, 2024
- 8-KBCPC
Jul 26, 2024
- Q1 2024
- 8-KBCPC
Jun 24, 2024
- 10-QBCPC
May 3, 2024
Earnings releases
7 documentsPresentations
5 documents
Transcripts
0 documentsNo transcripts for Balchem Corp are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.